Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 38 min ago
Peer-reviewedCC BYFrontiers in cellular and infection microbiology

Integrating Mendelian randomization with single-cell and spatial transcriptomics to investigate gut microbiota-associated genetic signals and molecular characteristics in prostate cancer.

5 affiliations
  1. 1Department of General Surgery, Changzhou Hospital of Traditional Chinese Medicine, Changzhou, China.
  2. 2Department of Neurosurgery, Jiangmen Central Hospital, Jiangmen, China.
  3. 3Department of Urology, Wujin Hospital Affiliated With Jiangsu University, Changzhou, China.
  4. 4Department of Urology, The Wujin Clinical College of Xuzhou Medical University, Changzhou, China.
  5. 5Department of Otolaryngology, Changzhou Medical Centre of the 904th Hospital, Chinese Logistics Support Force, Changzhou, China.

Abstract

Background

Prostate cancer (PRAD) represents one of the most prevalent malignancies among men globally. Accumulating evidence implicates gut microbiota dysbiosis in the initiation and progression of prostate cancer; however, the causal relationship and underlying molecular mechanisms remain incompletely elucidated. This study integrated Mendelian randomization (MR), bioinformatics, single-cell RNA sequencing, and spatial transcriptomics to systematically investigate the genetic associations between gut microbiota and prostate cancer risk and characterize the expression patterns of microbiota-associated candidate genes within the tumor microenvironment.Methods

Two-sample MR analyses were performed using summary statistics from the OpenGWAS database to evaluate causal associations between gut microbiota and PRAD risk, with sensitivity analyses conducted to ensure robustness. Significant SNPs were functionally annotated and mapped to candidate genes using g:SNPense, and differentially expressed associated genes (DEAGs) were identified through integration with GEO datasets. Subsequent analyses encompassed immune infiltration profiling, machine learning model construction, and nomogram validation. Single-cell RNA sequencing and spatial transcriptomics were employed to delineate cell type-specific expression and spatial distribution patterns of signature genes. Candidate gene expression alterations in prostate cancer cells were experimentally validated by quantitative real-time PCR (qRT-PCR).Results

MR analyses identified significant positive causal associations between PRAD risk and Brevibacillaceae, Brevibacillales, CAG-110, and Pararhizobium, whereas Lawsonibacter sp000492175 exhibited a significant inverse association. A total of 21 differentially expressed genes were identified, with RASSF3, CROCC, UBE4B, SMOC2, and ACACA emerging as key signature genes. Immune infiltration analyses revealed a significant positive correlation between FRMD3 and regulatory T cells (Tregs), and a negative correlation between ACACA and neutrophil infiltration. The random forest classifier demonstrated optimal predictive performance, achieving an area under the curve (AUC) of 0.853 in the validation cohort. Single-cell and spatial transcriptomic analyses revealed cell-type-associated expression patterns of ACACA, SMOC2, and UBE4B across different cellular populations. These findings suggest potential associations between signature genes and specific cellular contexts, which require further experimental validation. qRT-PCR validated differential expression patterns of these candidate genes in prostate cancer cells.Conclusion

This study provides genetic causal inference evidence supporting a close association between gut microbiota and prostate cancer risk, and identifies multiple key signature genes implicated in immune microenvironment regulation and tumor progression. Integrated single-cell and spatial transcriptomic analyses suggest that these genes exhibit distinct expression patterns among different cellular populations and may provide clues for understanding their potential roles in PRAD progression. These findings provide genetic evidence supporting the association between gut microbiota and prostate cancer risk and highlight potential microbiota-associated molecular signatures. Further functional studies are required to clarify whether these genes directly contribute to microbiota-related prostate cancer progression.

Related

  1. Exploring the relationship between gut microbiota and pan-cancer: a meta-analysis of Mendelian randomization studies
    Fangying Chen, Yuxuan Wu, Yu Zhang +2
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textMolecular biology & gene regulationCrossref
  2. Integrating QTL Mapping and Candidate-Region Association to Investigate Kernel Size and Weight in Sweet Corn
    Chongjing Ma, Jinrong Song, Jingtao Qu +12
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0General biochemistryCrossref
  3. Causal associations between gut microbiota and autism spectrum disorder and attention-deficit/hyperactivity disorder: a two-sample mendelian randomization study
    Shangyun Shi, Ancha Baranova, Hongbao Cao +1
    Frontiers in geneticsPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMCEurope PMCPMC
  4. Gut microbiota, sleep and coronary artery disease: A Mendelian randomization study.
    Ye-Dan Li, Hong Meng, Ran Qu +2
    MedicinePeer-reviewedCC BY-NCFull textMolecular biology & gene regulationEurope PMC
  5. Gut Microbiota, Inflammatory Bowel Disease and the Prioritization of Host Effector Genes: A Two-Sample Mendelian Randomization Study with Independent Replication, cis-eQTL Colocalization and Single-Cell Localization.
    Qiyuan Zou, Jianyi Wang
    International journal of molecular sciencesPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMC
BibTeX
@article{qiu2026integrating,
  title = {{Integrating Mendelian randomization with single-cell and spatial transcriptomics to investigate gut microbiota-associated genetic signals and molecular characteristics in prostate cancer.}},
  author = {Chenjie Qiu and Huilin Zhang and Zongmin Du and Yuan Gao and Liangliang Dai},
  journal = {Frontiers in cellular and infection microbiology},
  year = {2026},
  month = oct,
  doi = {10.3389/fcimb.2026.1899354},
  url = {https://europepmc.org/article/MED/42903126},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Integrating Mendelian randomization with single-cell and spatial transcriptomics to investigate gut microbiota-associated genetic signals and molecular characteristics in prostate cancer.
AU  - Chenjie Qiu
AU  - Huilin Zhang
AU  - Zongmin Du
AU  - Yuan Gao
AU  - Liangliang Dai
PY  - 2026
DA  - 2026/10/06
JO  - Frontiers in cellular and infection microbiology
DO  - 10.3389/fcimb.2026.1899354
UR  - https://europepmc.org/article/MED/42903126
AB  - Background  Prostate cancer (PRAD) represents one of the most prevalent malignancies among men globally. Accumulating evidence implicates gut microbiota dysbiosis in the initiation and progression of prostate cancer; however, the causal relationship and underlying molecular mechanisms remain incompletely elucidated. This study integrated Mendelian randomization (MR), bioinformatics, single-cell RNA sequencing, and spatial transcriptomics to systematically investigate the genetic associations between gut microbiota and prostate cancer risk and characterize the expression patterns of microbiota-associated candidate genes within the tumor microenvironment.Methods  Two-sample MR analyses were performed using summary statistics from the OpenGWAS database to evaluate causal associations between gut microbiota and PRAD risk, with sensitivity analyses conducted to ensure robustness. Significant SNPs were functionally annotated and mapped to candidate genes using g:SNPense, and differentially expressed associated genes (DEAGs) were identified through integration with GEO datasets. Subsequent analyses encompassed immune infiltration profiling, machine learning model construction, and nomogram validation. Single-cell RNA sequencing and spatial transcriptomics were employed to delineate cell type-specific expression and spatial distribution patterns of signature genes. Candidate gene expression alterations in prostate cancer cells were experimentally validated by quantitative real-time PCR (qRT-PCR).Results  MR analyses identified significant positive causal associations between PRAD risk and Brevibacillaceae, Brevibacillales, CAG-110, and Pararhizobium, whereas Lawsonibacter sp000492175 exhibited a significant inverse association. A total of 21 differentially expressed genes were identified, with RASSF3, CROCC, UBE4B, SMOC2, and ACACA emerging as key signature genes. Immune infiltration analyses revealed a significant positive correlation between FRMD3 and regulatory T cells (Tregs), and a negative correlation between ACACA and neutrophil infiltration. The random forest classifier demonstrated optimal predictive performance, achieving an area under the curve (AUC) of 0.853 in the validation cohort. Single-cell and spatial transcriptomic analyses revealed cell-type-associated expression patterns of ACACA, SMOC2, and UBE4B across different cellular populations. These findings suggest potential associations between signature genes and specific cellular contexts, which require further experimental validation. qRT-PCR validated differential expression patterns of these candidate genes in prostate cancer cells.Conclusion  This study provides genetic causal inference evidence supporting a close association between gut microbiota and prostate cancer risk, and identifies multiple key signature genes implicated in immune microenvironment regulation and tumor progression. Integrated single-cell and spatial transcriptomic analyses suggest that these genes exhibit distinct expression patterns among different cellular populations and may provide clues for understanding their potential roles in PRAD progression. These findings provide genetic evidence supporting the association between gut microbiota and prostate cancer risk and highlight potential microbiota-associated molecular signatures. Further functional studies are required to clarify whether these genes directly contribute to microbiota-related prostate cancer progression.
SN  - 2235-2988
ER  -